RHHBF - Novo Nordisk: Leading The Fight Against Diabetes And Obesity

2024-06-18 11:26:22 ET

Summary

• Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases.
• The company's share price reflects optimism about its diabetes franchise, promising results in treating patients with hemophilia A and progress with CagriSema.
• A more promising experimental drug relative to CagriSema is amycretin, which demonstrated a 13.1% reduction in patient weight after just 12 weeks of treatment.
• On the other hand, sales of Ozempic, Novo Nordisk's blockbuster, were DKK 27.81 billion in the first quarter of 2024, up 41.6% year-on-year.
• Consequently, I'm initiating coverage of Novo Nordisk with a "buy" rating.

Novo Nordisk ( NVO ) ( NONOF ) is one of the key players in the global type 2 diabetes treatment market.

Investment thesis

Novo Nordisk's share price has continued to move in an upward trend in recent months, reflecting traders' and investors' optimism about the development of its multi-billion dollar diabetes franchise, the recent publication of promising results from a Phase 3a clinical trial that showed that once-weekly and once-monthly Mim8 was able to statistically significantly lower the number of bleeding episodes in people with hemophilia A, and significant progress in the development of CagriSema, which has demonstrated extremely high efficacy in the fight against obesity and type 2 diabetes....

For further details see: